{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:13:21Z","timestamp":1793420001952,"version":"4.5.0"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.pharmthera.2020.107473","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T19:37:42Z","timestamp":1578512262000},"page":"107473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Recent advances in bone-targeted therapy"],"prefix":"10.1016","volume":"207","author":[{"given":"Chen","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107473_bb0005","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3631764","article-title":"Osteosarcoma: Cells-of-origin, cancer stem cells, and targeted therapies","volume":"2016","author":"Abarrategi","year":"2016","journal-title":"Stem Cells International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","article-title":"Atrial fibrillation in fracture patients treated with oral bisphosphonates","volume":"265","author":"Abrahamsen","year":"2009","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0030","first-page":"280","article-title":"Regulatory mechanisms of bone development and function","volume":"3","author":"Ahmed","year":"2015","journal-title":"International Journal of Advanced Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/177433a0","article-title":"Avidity of the tetracyclines for the cations of metals","volume":"177","author":"Albert","year":"1956","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biocel.2015.05.008","article-title":"Extracellular matrix networks in bone remodeling","volume":"65","author":"Alford","year":"2015","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11914-013-0184-x","article-title":"Stem cell therapy for osteoporosis","volume":"12","author":"Antebi","year":"2014","journal-title":"Current Osteoporosis Reports"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0050","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.addr.2012.05.017","article-title":"Peptide-based delivery to bone","volume":"64","author":"Aoki","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0055","article-title":"Junctions between early developing osteoblasts of rat calvaria as revealed by freeze-fracture and ultrathin section electron microscopy.","volume":"3","author":"Arana-Chavez","year":"1995","journal-title":"Archives of Histology and Cytology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00016348209155328","article-title":"On the role of estrogens in endometrial carcinogenesis","volume":"61","author":"\u00c5stedt","year":"1982","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0065","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.matbio.2008.06.004","article-title":"Bone sialoprotein-collagen interaction promotes hydroxyapatite nucleation","volume":"27","author":"Baht","year":"2008","journal-title":"Matrix Biology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0070","doi-asserted-by":"crossref","first-page":"R152","DOI":"10.1186\/ar3103","article-title":"Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis","volume":"12","author":"Bellido","year":"2010","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0075","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/00220345610400050201","article-title":"The effect of the administration of tetracycline on the development of teeth","volume":"40","author":"Bevelander","year":"1961","journal-title":"Journal of Dental Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2010.04.015","article-title":"Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin","volume":"394","author":"Bhandari","year":"2010","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-014-0325-1","article-title":"Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases","volume":"16","author":"Blacksburg","year":"2015","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0090","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bone.2008.05.024","article-title":"The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients","volume":"43","author":"Boivin","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1749-6632.1995.tb44635.x","article-title":"Osteopontin and related phosphorylated sialoproteins: Effects on mineralizationa","volume":"760","author":"Boskey","year":"1995","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0100","first-page":"324","article-title":"Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays","volume":"60","author":"Brown","year":"2014","journal-title":"Canadian Family Physician"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0105","series-title":"Basic and applied bone biology","first-page":"3","article-title":"Bone morphology and organization","author":"Burr","year":"2019"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2014.05.003","article-title":"Osteoblast and osteocyte: Games without frontiers","volume":"561","author":"Capulli","year":"2014","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nano.2016.08.015","article-title":"Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties","volume":"13","author":"Carbone","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0120","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1166\/jnn.2017.12855","article-title":"Osteotropic nanoscale drug delivery system via a single aspartic acid as the bone-targeting moiety","volume":"17","author":"Carbone","year":"2017","journal-title":"Journal of Nanoscience and Nanotechnology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0125","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/ic502425e","article-title":"Ion exchange in hydroxyapatite with lanthanides","volume":"54","author":"Cawthray","year":"2015","journal-title":"Inorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/path.1711360104","article-title":"Calcitonin alters behaviour of isolated osteoclasts","volume":"136","author":"Chambers","year":"1982","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/00313020600696231","article-title":"Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy","volume":"38","author":"Chan","year":"2006","journal-title":"Pathology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0380","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molmed.2014.06.001","article-title":"Osteoclasts: More than \u201cbone eaters\u201d","volume":"20","author":"Charles","year":"2014","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2017.09.011","article-title":"A novel bone targeting delivery system carrying phytomolecule icaritin for prevention of steroid-associated osteonecrosis in rats","volume":"106","author":"Chen","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0145","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.drudis.2017.04.021","article-title":"Development of nanomaterials for bone-targeted drug delivery","volume":"22","author":"Cheng","year":"2017","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0150","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cncr.10788","article-title":"Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival","volume":"95","author":"Cheville","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0090-6980(84)90223-5","article-title":"Stimulation of bone formation by prostaglandin E2","volume":"27","author":"Chyun","year":"1984","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0160","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0165","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0170","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1172\/JCI70050","article-title":"Bone marrow mesenchymal stem cells and TGF-\u03b2 signaling in bone remodeling","volume":"124","author":"Crane","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: The importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/aps.2009.9","article-title":"Osteogenic effects of D (+) \u03b2-3, 4-dihydroxyphenyl lactic acid (salvianic acid A, SAA) on osteoblasts and bone marrow stromal cells of intact and prednisone-treated rats","volume":"30","author":"Cui","year":"2009","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0185","first-page":"1193","article-title":"New roles of osteocytes in proliferation, migration and invasion of breast and prostate cancer cells","volume":"36","author":"Cui","year":"2016","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0190","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0195","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/term.1851","article-title":"The role of osteoclasts in bone tissue engineering","volume":"9","author":"Detsch","year":"2015","journal-title":"Journal of Tissue Engineering and Regenerative Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0200","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/mp400366r","article-title":"The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma","volume":"11","author":"Dhule","year":"2014","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0205","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp8002368","article-title":"Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis","volume":"6","author":"Doschak","year":"2009","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/ptj\/86.1.77","article-title":"Bone biology and the clinical implications for osteoporosis","volume":"86","author":"Downey","year":"2006","journal-title":"Physical Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0215","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0220","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.22455","article-title":"Markers of angiogenesis and clinical features in patients with sarcoma","volume":"109","author":"DuBois","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0230","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bmcl.2007.11.029","article-title":"Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation","volume":"18","author":"Erez","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107473_bb0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1359\/jbmr.2002.17.1.77","article-title":"The bone lining cell: its role in cleaning Howship\u2019s lacunae and initiating bone formation","author":"Everts","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0240","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biopha.2016.11.132","article-title":"Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle","volume":"85","author":"Fang","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0565","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02065192","article-title":"The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo","volume":"2","author":"M\u00fchlbauer","year":"1968","journal-title":"Calcified Tissue Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1155\/2015\/421746","article-title":"Biology of bone tissue: Structure, function, and factors that influence bone cells","volume":"2015","author":"Florencio-Silva","year":"2015","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0250","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/dvdy.20603","article-title":"Buried alive: How osteoblasts become osteocytes","volume":"235","author":"Franz-Odendaal","year":"2006","journal-title":"Developmental Dynamics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0255","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1016\/j.actbio.2014.07.015","article-title":"Aspartic acid-based modified PLGA\u2013PEG nanoparticles for bone targeting: In vitro and in vivo evaluation","volume":"10","author":"Fu","year":"2014","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0260","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0968-0896(99)00045-0","article-title":"Prostaglandin E2-bisphosphonate conjugates: Potential agents for treatment of osteoporosis","volume":"7","author":"Gil","year":"1999","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0265","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I","article-title":"The role of the chondrocyte in osteoarthritis","volume":"43","author":"Goldring","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0270","first-page":"143","article-title":"Bone and cartilage in osteoarthritis: Is what\u2019s best for one good or bad for the other?","volume":"12","author":"Goldring","year":"2010"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0275","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ijos.2017.28","article-title":"Doxycycline induces bone repair and changes in Wnt signalling","volume":"9","author":"Gomes","year":"2017","journal-title":"International Journal of Oral Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0280","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bone.2014.07.033","article-title":"Bone fracture healing: Cell therapy in delayed unions and nonunions","volume":"70","author":"Gomez-Barrena","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0285","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrendo.2014.234","article-title":"Stromal cells and stem cells in clinical bone regeneration","volume":"11","author":"Grayson","year":"2015","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0290","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case-control analysis within a UK primary care cohort","volume":"341","author":"Green","year":"2010","journal-title":"British Medical Journal"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0295","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0300","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nm.2665","article-title":"Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass","volume":"18","author":"Guan","year":"2012","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0305","first-page":"1027","article-title":"Diagnosis and management of osteomyelitis","volume":"84","author":"Hatzenbuehler","year":"2011","journal-title":"American Family Physician"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nature11000","article-title":"Osteoprotection by semaphorin 3A","volume":"485","author":"Hayashi","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0315","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2017.08.024","article-title":"Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer","volume":"264","author":"He","year":"2017","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0320","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijpharm.2006.11.024","article-title":"Bone targeting potential of bisphosphonate-targeted liposomes: Preparation, characterization and hydroxyapatite binding in vitro","volume":"331","author":"Hengst","year":"2007","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0325","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrrheum.2013.113","article-title":"Osteoarthritis: Osteoporotic OA: A reasonable target for bone-acting agents","volume":"9","author":"Herrero-Beaumont","year":"2013","journal-title":"Nature Reviews Rheumatology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0330","doi-asserted-by":"crossref","first-page":"615486","DOI":"10.1155\/2015\/615486","article-title":"Mechanisms of bone resorption in periodontitis","volume":"2015","author":"Hienz","year":"2015","journal-title":"Journal of Immunology Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0335","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003088-200342150-00002","article-title":"Bone-specific drug delivery systems: Approaches via chemical modification of bone-seeking agents","volume":"42","author":"Hirabayashi","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0345","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/cr.2015.7","article-title":"Characterization and target identification of a DNA aptamer that labels pluripotent stem cells","volume":"25","author":"Hou","year":"2015","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0350","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201605235","article-title":"A difunctional regeneration scaffold for knee repair based on aptamer-directed cell recruitment","volume":"29","author":"Hu","year":"2017","journal-title":"Advanced Materials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0355","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1073\/pnas.90.18.8562","article-title":"Nucleation of hydroxyapatite by bone sialoprotein","volume":"90","author":"Hunter","year":"1993","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0360","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/sj.mt.6300218","article-title":"Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles","volume":"15","author":"Itaka","year":"2007","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0365","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0169-6009(91)90109-D","article-title":"Long-term anabolic effects of prostaglandin-E2 on tibial diaphyseal bone in male rats","volume":"15","author":"Jee","year":"1991","journal-title":"Bone and Mineral"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0370","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bone.2013.05.020","article-title":"MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1","volume":"56","author":"Ji","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0375","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijpharm.2014.08.067","article-title":"Poly aspartic acid peptide-linked PLGA based nanoscale particles: Potential for bone-targeting drug delivery applications","volume":"475","author":"Jiang","year":"2014","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0385","article-title":"Selective drug delivery to bone using acidic oligopeptides","volume":"1","author":"Junko","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0395","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1210\/er.2008-0002","article-title":"Osteoporosis in men","volume":"29","author":"Khosla","year":"2008","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0400","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: Recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0405","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.24330","article-title":"Stromal cell-derived factor 1\/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model","volume":"60","author":"Kitaori","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0410","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1582-4934.2006.tb00287.x","article-title":"Tissue engineering of bone: the reconstructive surgeon\u2019s point of view","volume":"10","author":"Kneser","year":"2006","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0415","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1083\/jcb.115.4.1179","article-title":"Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface","volume":"115","author":"Lakkakorpi","year":"1991","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2016.08.002","article-title":"Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases","volume":"91","author":"Lange","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0425","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/annrheumdis-2012-202989","article-title":"Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: Data from the Osteoarthritis Initiative","volume":"73","author":"Laslett","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0430","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jbm.b.31500","article-title":"Differences between bisphosphonates in binding affinities for hydroxyapatite","volume":"92B","author":"Lawson","year":"2010","journal-title":"Journal of Biomedical Materials Research. Part B, Applied Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0435","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11914-017-0353-4","article-title":"Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy","volume":"15","author":"Leder","year":"2017","journal-title":"Current Osteoporosis Reports"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0440","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1039\/C8RA09729A","article-title":"Bone-targeting carbon dots: effect of nitrogen-doping on binding affinity","volume":"9","author":"Lee","year":"2019","journal-title":"RSC Advances"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0445","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0450","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/os.12238","article-title":"Advances in bone-targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma","volume":"8","author":"Li","year":"2016","journal-title":"Orthopaedic Surgery"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0455","article-title":"Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation","volume":"7","author":"Li","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0460","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biomaterials.2015.09.046","article-title":"Healing of osteoporotic bone defects by baculovirus-engineered bone marrow-derived MSCs expressing MicroRNA sponges","volume":"74","author":"Li","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0465","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbrc.2006.02.147","article-title":"Osteoclast and its roles in calcium metabolism and bone development and remodeling","volume":"343","author":"Li","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0470","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.3791","article-title":"Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy","volume":"21","author":"Liang","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0475","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biomaterials.2017.09.015","article-title":"Tumor cell-targeted delivery of CRISPR\/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma","volume":"147","author":"Liang","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0480","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jot.2017.03.002","article-title":"Mesenchymal stem cells homing to improve bone healing","volume":"9","author":"Lin","year":"2017","journal-title":"Journal of Orthopaedic Translation"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0485","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0490","doi-asserted-by":"crossref","first-page":"100801","DOI":"10.1016\/j.nantod.2019.100801","article-title":"Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer","volume":"29","author":"Liu","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0495","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.nano.2018.07.011","article-title":"Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice","volume":"14","author":"Liu","year":"2018","journal-title":"Nanomedicine: Nanotechnology, Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0500","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addr.2012.01.012","article-title":"Targeting polymer therapeutics to bone","volume":"64","author":"Low","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0505","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1021\/bc500392x","article-title":"Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics","volume":"25","author":"Low","year":"2014","journal-title":"Bioconjugate Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0510","first-page":"31","article-title":"Comparative study of tetracycline-estrone and estrone effects on bone histomorphometric parameters in ovariectomized rats","volume":"33","author":"Lu","year":"1998","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0515","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/erm.09.15","article-title":"Current advances in research and clinical applications of PLGA-based nanotechnology","volume":"9","author":"Lu","year":"2009","journal-title":"Expert Review of Molecular Diagnostics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0520","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0026-895X(24)23047-9","article-title":"Prostaglandin receptor EP4 mediates the bone anabolic effects of PGE2","volume":"60","author":"Machwate","year":"2001","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aja.1001830102","article-title":"Bone cell biology: the regulation of development, structure, and function in the skeleton","volume":"183","author":"Marks","year":"1988","journal-title":"The American Journal of Anatomy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0530","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bone.2006.08.003","article-title":"Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget\u2019s disease of bone","volume":"40","author":"Martini","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0535","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/stem.2474","article-title":"Quiescent bone lining cells are a major source of osteoblasts during adulthood","volume":"34","author":"Matic","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0540","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1074\/jbc.273.6.3643","article-title":"A study of the collagen-binding domain of a 116-kDa clostridium histolyticum collagenase","volume":"273","author":"Matsushita","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0545","doi-asserted-by":"crossref","DOI":"10.1007\/s10856-018-6046-4","article-title":"\u201cRuffled border\u201d formation on a CaP-free substrate: A first step towards osteoclast-recruiting bone-grafts materials able to re-establish bone turn-over","volume":"29","author":"Merolli","year":"2018","journal-title":"Journal of Materials Science. Materials in Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0550","first-page":"953","article-title":"Bone lining cells: Structure and function","volume":"3","author":"Miller","year":"1989","journal-title":"Scanning Microscopy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0555","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/ar3373","article-title":"Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model","volume":"13","author":"Moreau","year":"2011","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0560","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/8756-3282(93)90235-3","article-title":"Increased intracortical remodeling following fatigue damage","volume":"14","author":"Mori","year":"1993","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0570","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0575","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF02405117","article-title":"IR absorption spectrophotometric analysis of the complex formed by tetracycline and synthetic hydroxyapatite","volume":"35","author":"Myers","year":"1983","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10520290009047977","article-title":"Histology and tetracycline labeling of a single section of alveolar bone of first molars in the rat","volume":"75","author":"Nakamura","year":"2000","journal-title":"Biotechnic & Histochemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0585","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0590","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bmcl.2008.12.051","article-title":"Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent","volume":"19","author":"Neale","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0595","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0600","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bonekey.2012.183","article-title":"Bone cell communication factors and semaphorins","volume":"1","author":"Negishi-Koga","year":"2012","journal-title":"BoneKEy Reports"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0605","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin\u20131 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0610","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0615","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Current Drug Targets"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107473_bb0620","first-page":"85","article-title":"Critical analysis of the evidence for current technologies in bone-healing and repair","volume":"90","author":"Novicoff","year":"2008","journal-title":"The Journal of Bone and Joint Surgery. American Volume"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0625","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/430161a","article-title":"The RNAi revolution","volume":"430","author":"Novina","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0630","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jbmr.2182","article-title":"Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL","volume":"29","author":"Ohba","year":"2014","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0635","doi-asserted-by":"crossref","first-page":"19430","DOI":"10.1016\/S0021-9258(19)77651-0","article-title":"The primary structure of a cell-binding bone sialoprotein","volume":"263","author":"Oldberg","year":"1988","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0640","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1517\/17425247.2015.1021679","article-title":"Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering","volume":"12","author":"Ossipov","year":"2015","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0645","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biomaterials.2016.05.007","article-title":"A novel small-molecule PPI inhibitor targeting integrin \u03b1v\u03b23-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice","volume":"98","author":"Park","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0650","first-page":"325","article-title":"Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis","volume":"6","author":"Pazianas","year":"2010","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0655","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02796203","article-title":"Prostate cancer: A comprehensive review","volume":"17","author":"Pentyala","year":"2000","journal-title":"Medical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0660","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/gt.2015.16","article-title":"Intra-articular delivery of anti-Hif-2\u03b1 siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice","volume":"22","author":"Pi","year":"2015","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0665","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1016\/j.biomaterials.2011.05.017","article-title":"Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display","volume":"32","author":"Pi","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0670","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2013.07.015","article-title":"Treating osteoporosis by targeting parathyroid hormone to bone","volume":"19","author":"Ponnapakkam","year":"2014","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0675","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00223-012-9626-1","article-title":"A single injection of the anabolic bone agent, parathyroid hormone\u2013collagen binding domain (PTH\u2013CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice","volume":"91","author":"Ponnapakkam","year":"2012","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0680","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0685","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2016.02.003","article-title":"Osteocytes: The master cells in bone remodelling","volume":"28","author":"Prideaux","year":"2016","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0690","first-page":"1845","article-title":"Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States","volume":"25","author":"Qian","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0695","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1021\/acsnano.7b03197","article-title":"Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release","volume":"11","author":"Qiao","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.11","article-title":"Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK\/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model","volume":"7","author":"Qiao","year":"2016","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0705","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10555-006-9031-1","article-title":"Anti-angiogenic therapy for osteosarcoma","volume":"25","author":"Quan","year":"2006","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0710","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: Now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0715","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cgt.2011.83","article-title":"Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma","volume":"19","author":"Rainusso","year":"2012","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0720","doi-asserted-by":"crossref","first-page":"141ra193","DOI":"10.1126\/scitranslmed.3003720","article-title":"A tissue engineering solution for segmental defect regeneration in load-bearing long bones","volume":"4","author":"Reichert","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0725","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0730","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulators\u2014mechanisms of action and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0735","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.biocel.2013.08.018","article-title":"The NF-\u03baB signalling pathway in osteoarthritis","volume":"45","author":"Rigoglou","year":"2013","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0740","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00198-010-1194-5","article-title":"Osteocyte: The unrecognized side of bone tissue","volume":"21","author":"Rochefort","year":"2010","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0745","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0750","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jconrel.2017.11.009","article-title":"Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics","volume":"269","author":"Rotman","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0755","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2016.04.025","article-title":"Bone-targeted delivery of nanodiamond-based drug carriers conjugated with alendronate for potential osteoporosis treatment","volume":"232","author":"Ryu","year":"2016","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0760","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2741\/4026","article-title":"Acidic bone matrix proteins and their roles in calcification","volume":"17","author":"Ryuichi Fujisawa","year":"2012","journal-title":"Frontiers in Bioscience"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0765","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-4632.2004.02108.x","article-title":"Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity","volume":"43","author":"S\u00e1nchez","year":"2004","journal-title":"International Journal of Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0770","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0775","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10611860108997922","article-title":"Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential","volume":"9","author":"Sekido","year":"2001","journal-title":"Journal of Drug Targeting"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0780","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0785","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.addr.2004.12.017","article-title":"Skeletal function and structure: Implications for tissue-targeted therapeutics","volume":"57","author":"Shea","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0790","doi-asserted-by":"crossref","first-page":"27511","DOI":"10.1021\/acsami.6b08685","article-title":"Demineralized bone matrix scaffolds modified by CBD-SDF-1\u03b1 promote bone regeneration via recruiting endogenous stem cells","volume":"8","author":"Shi","year":"2016","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0795","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0800","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: anabolic and catabolic actions on the skeleton","volume":"22","author":"Silva","year":"2015","journal-title":"Current Opinion in Pharmacology"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107473_bb0805","first-page":"S86","article-title":"Biology of bone and how it orchestrates the form and function of the skeleton","volume":"10","author":"Sommerfeldt","year":"2001","journal-title":"European Spine Journal"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0810","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-targeted therapies in cancer-induced bone disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0815","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.5966\/sctm.2015-0347","article-title":"Allogeneic mesenchymal stem cell therapy promotes osteoblastogenesis and prevents glucocorticoid-induced osteoporosis","volume":"5","author":"Sui","year":"2016","journal-title":"Stem Cells Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0820","article-title":"Controlled release of collagen-binding SDF-1\u03b1 improves cardiac function after myocardial infarction by recruiting endogenous stem cells","volume":"6","author":"Sun","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-6798.1000e103","article-title":"Modern chemistry and applications peptide-based drug development advantages and disadvantages","volume":"1","author":"Sun","year":"2013","journal-title":"Modern Chemistry and Applications"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0830","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1021\/acsnano.5b07828","article-title":"Osteoblast-targeting-peptide modified nanoparticle for siRNA\/microRNA delivery","volume":"10","author":"Sun","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0835","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jor.24227","article-title":"Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma","volume":"37","author":"Tang","year":"2019","journal-title":"Journal of Orthopaedic Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0840","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0845","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1021\/acsnano.5b06189","article-title":"Identification of dormancy-associated microRNAs for the design of osteosarcoma-targeted dendritic polyglycerol nanopolyplexes","volume":"10","author":"Tiram","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0850","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1211\/0022357001773652","article-title":"Tissue distribution and pharmacological potential of sm-16896, a novel oestrogen-bisphosphonate hybrid compound","volume":"52","author":"Tsushima","year":"2000","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0855","article-title":"Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice. %J Calcified tissue international","volume":"6","author":"Tulasi","year":"2011","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0860","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41687-018-0054-5","article-title":"Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)","volume":"2","author":"Unger","year":"2017","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0865","first-page":"129","article-title":"Safety and efficacy of doxycycline in the treatment of rosacea","volume":"2","author":"Valent\u00edn","year":"2009","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0870","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcb.25291","article-title":"Biology and treatment of Paget\u2019s disease of bone","volume":"117","author":"Vallet","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0875","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bone.2009.10.028","article-title":"RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis","volume":"46","author":"Verdrengh","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0880","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/ar4053","article-title":"Biologic adjuvants for fracture healing","volume":"14","author":"Virk","year":"2012","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0885","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0015-0282(16)46149-2","article-title":"The menopause: benefits and risks of estrogen-progestogen replacement therapy","volume":"37","author":"Wallach","year":"1982","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0890","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.addr.2004.12.011","article-title":"Bone-targeting macromolecular therapeutics","volume":"57","author":"Wang","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0895","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.280.5366.1077","article-title":"Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome","volume":"280","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0900","first-page":"5671","article-title":"Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system","volume":"10","author":"Wang","year":"2015","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0905","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jcis.2010.04.081","article-title":"Studies on the sorption of tetracycline onto clays and marine sediment from seawater","volume":"349","author":"Wang","year":"2010","journal-title":"Journal of Colloid and Interface Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0910","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1007\/s13277-014-1637-2","article-title":"miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0915","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00253-003-1442-0","article-title":"Collagenolytic proteases from bacteria","volume":"63","author":"Watanabe","year":"2004","journal-title":"Applied Microbiology and Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0920","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031237","article-title":"Regulation of bone remodeling by parathyroid hormone","volume":"8","author":"Wein","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0925","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3181\/00379727-186-42590A","article-title":"Bone-targeted carbonic anhydrase inhibitors: Effect of a proinhibitor on bone resorption in vitro","volume":"186","author":"William","year":"1987","journal-title":"Experimental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb2005","doi-asserted-by":"crossref","first-page":"9422","DOI":"10.1016\/j.biomaterials.2010.08.064","article-title":"Phosphorylation-dependent mineral-type specificity for apatite-binding peptide sequences","volume":"31","author":"William","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0930","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-016-0223-x","article-title":"Advancement and applications of peptide phage display technology in biomedical science","volume":"23","author":"Wu","year":"2016","journal-title":"Journal of Biomedical Science"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0935","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/nm.2793","article-title":"Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells","volume":"18","author":"Xian","year":"2012","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0940","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1021\/acs.jmedchem.6b00951","article-title":"Design, synthesis, and pharmacokinetics of a bone-targeting dual-action prodrug for the treatment of osteoporosis","volume":"60","author":"Xie","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0945","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3892\/or.2017.5735","article-title":"Anti-angiogenesis target therapy for advanced osteosarcoma (Review)","volume":"38","author":"Xie","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0950","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1096\/fj.14-254169","article-title":"Sox11-modified mesenchymal stem cells (MSCs) accelerate bone fracture healing: Sox11 regulates differentiation and migration of MSCs","volume":"29","author":"Xu","year":"2015","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0955","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/jbmr.2790","article-title":"Skeletal mineralization deficits and impaired biogenesis and function of chondrocyte-derived matrix vesicles in phospho1(-\/-) and phospho1\/pi t1 double-knockout mice","volume":"31","author":"Yadav","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0960","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bone.2018.06.003","article-title":"A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice","volume":"114","author":"Yang","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0965","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1359\/jbmr.2003.18.4.705","article-title":"In vitro and in vivo synergistic interactions between the Runx2\/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation","volume":"18","author":"Yang","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0970","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00223-009-9312-0","article-title":"Specific binding and mineralization of calcified surfaces by small peptides","volume":"86","author":"Yarbrough","year":"2010","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0975","series-title":"Chemistry","first-page":"2012","article-title":"Bifunctional bisphosphonates for delivering biomolecules to bone","author":"Yewle","year":"2012"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0980","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.142.3.8024","article-title":"Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice","volume":"142","author":"Yokogawa","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0985","first-page":"2096","article-title":"Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice","volume":"63","author":"Yonou","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0990","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm.2617","article-title":"A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy","volume":"18","author":"Zhang","year":"2012","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb0995","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.mattod.2015.11.008","article-title":"Carbon dots: large-scale synthesis, sensing and bioimaging","volume":"19","author":"Zhang","year":"2016","journal-title":"Materials Today"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1000","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.2018.36.15_suppl.5049","article-title":"Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases","volume":"36","author":"Zhang","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","article-title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis","volume":"4","author":"Zhao","year":"2006","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1010","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1039\/C7NR00962C","article-title":"Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption","volume":"9","author":"Zhao","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2019.104785","article-title":"Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation","volume":"223","author":"Zhao","year":"2019","journal-title":"Chemistry and Physics of Lipids"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1020","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/onc.2014.113","article-title":"Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis","volume":"34","author":"Zhou","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1025","first-page":"301","article-title":"Advances in targeted therapy for osteosarcoma","volume":"17","author":"Zhou","year":"2014","journal-title":"Discovery Medicine"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1030","doi-asserted-by":"crossref","first-page":"18387","DOI":"10.1039\/C8NR03899F","article-title":"Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy","volume":"10","author":"Zhu","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.pharmthera.2020.107473_bb1035","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/ijms18102142","article-title":"Recent advances in selex technology and aptamer applications in biomedicine","volume":"18","author":"Zhuo","year":"2017","journal-title":"International Journal of Molecular Sciences"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:03:14Z","timestamp":1759010594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":207,"alternative-id":["S0163725820300012"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107473","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in bone-targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107473"}}